Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dillazep and the camp phosphodiesterase inhibitor, RA 233
- 1 July 1986
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 43 (2) , 161-175
- https://doi.org/10.1016/0049-3848(86)90057-5
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- The electronic aggregometer: A novel device for assessing platelet behavior in bloodPublished by Elsevier ,2002
- Dipyridamole: A Critical EvaluationDrug Intelligence & Clinical Pharmacy, 1984
- Therapy of Ischemic Cerebral Vascular Disease Due to AtherothrombosisNew England Journal of Medicine, 1984
- Mechanism of action of dipyridamoleThrombosis Research, 1983
- Dipyridamole kineticsClinical Pharmacology & Therapeutics, 1982
- DIPYRIDAMOLE AND OTHER PHOSPHODIESTERASE INHIBITORS ACT AS ANTITHROMBOTIC AGENTS BY POTENTIATING ENDOGENOUS PROSTACYCLINThe Lancet, 1978
- Inhibition of adenosine uptake in human erythrocytes by adenosine-5'-carboxamides, xylosyladenine, dipyridamole, hexobendine, and p-nitrobenzylthioguanosineBiochemical Pharmacology, 1978
- The effect of dipyridamole on platelet function: correlation with blood levels in man.British Journal of Clinical Pharmacology, 1977
- Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: Possible explanation of mechanism of inhibition of platelet functionLife Sciences, 1975
- Influence of a Pyrimidopyrimidine Derivative on Deamination of Adenosine by BloodCirculation Research, 1964